JP2006206461A - Composition for prevention/treatment of allergic disease - Google Patents
Composition for prevention/treatment of allergic disease Download PDFInfo
- Publication number
- JP2006206461A JP2006206461A JP2005017654A JP2005017654A JP2006206461A JP 2006206461 A JP2006206461 A JP 2006206461A JP 2005017654 A JP2005017654 A JP 2005017654A JP 2005017654 A JP2005017654 A JP 2005017654A JP 2006206461 A JP2006206461 A JP 2006206461A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- prevention
- allergic diseases
- diarsenic trioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、アレルギー疾患の予防・治療用組成物に関し、特に気管支喘息に対する根源的な予防・治療に用いられる組成物に関する。 The present invention relates to a composition for prevention / treatment of allergic diseases, and particularly to a composition used for fundamental prevention / treatment of bronchial asthma.
アトピー性皮膚炎、喘息、花粉症などのアレルギー疾患の増加は、大きな社会問題となっている。
これまでに、アレルギー疾患の予防・治療のために多くの医薬品や漢方薬が開発され、また各種薬草などが民間に伝承されている。さらに、日常的に飲用されている茶の成分であるカテキン類が有効であることも知られている。
An increase in allergic diseases such as atopic dermatitis, asthma and hay fever has become a major social problem.
So far, many medicines and herbal medicines have been developed for the prevention and treatment of allergic diseases, and various medicinal herbs have been handed down to the private sector. It is also known that catechins, which are components of tea that are drunk daily, are effective.
しかし、アレルギー疾患の予防や治療に用いられている医薬品などの中には、ステロイド薬が含まれることがあり、その副作用は憂慮すべき事態である。
そこで、本発明はこのような心配のない安全性の高いアレルギー疾患の予防・治療用組成物の提供を目的とするものである。
However, some of the medicines used for the prevention and treatment of allergic diseases may contain steroid drugs, and their side effects are an alarming situation.
Accordingly, an object of the present invention is to provide a highly safe composition for preventing and treating allergic diseases that is free from such concerns.
すなわち、請求項１記載の本発明は、三酸化二砒素を含有することを特徴とするアレルギー疾患の予防・治療用組成物である。
請求項２記載の本発明は、三酸化二砒素が、可食性粉末で５０〜２００倍に希釈されたものである請求項１記載のアレルギー疾患の予防・治療用組成物である。
また、請求項３記載の本発明は、三酸化二砒素と共に、桂枝、黄耆及び甘草の中の少なくとも１種の物質を含有する請求項１または２記載のアレルギー疾患の予防・治療用組成物である。
That is, the present invention according to claim 1 is a composition for preventing / treating allergic diseases, characterized by containing diarsenic trioxide.
The present invention according to claim 2 is the composition for prevention and treatment of allergic diseases according to claim 1, wherein diarsenic trioxide is diluted 50 to 200 times with edible powder.
Further, the present invention according to claim 3 is a composition for preventing / treating allergic diseases according to claim 1 or 2, comprising diarsenic trioxide and at least one substance selected from katsushi branch, jaundice and licorice. It is a thing.
本発明によれば、副作用がなく安全性の高い、気管支喘息などのアレルギー疾患を予防および／または治療するための組成物が提供される。 According to the present invention, there is provided a composition for preventing and / or treating allergic diseases such as bronchial asthma having no side effects and high safety.
上記したように、請求項１に係る本発明のアレルギー疾患予防・治療用組成物は、三酸化二砒素を含有するものである。
三酸化二砒素（AS2O３）は、俗に亜ヒ酸とも称されている物質である。本発明においては、該三酸化二砒素は、請求項２に記載したように、可食性粉末で５０〜２００倍に希釈された状態で用いられる。
組成物中における三酸化二砒素の含有量については、０．００５〜０．２ｇ、好ましくは０．０１〜０．１ｇ、より好ましくは０．０１〜０．０５ｇである。
As described above, the allergic disease prevention / treatment composition of the present invention according to claim 1 contains diarsenic trioxide.
Diarsenic trioxide (AS 2 O 3 ) is a substance commonly called arsenous acid. In the present invention, as described in claim 2, the diarsenic trioxide is used in a state diluted 50 to 200 times with edible powder.
About content of diarsenic trioxide in a composition, it is 0.005-0.2g, Preferably it is 0.01-0.1g, More preferably, it is 0.01-0.05g.
可食性粉末としては、デンプン、小麦粉などが用いられる。三酸化二砒素は、該可食性粉末によって５０〜２００倍、好ましくは７０〜１７０倍程度に希釈して用いる。
希釈倍率が下限未満であると、毒性の影響が心配され、上限を超えると、十分な薬効が期待できない場合がある。
As the edible powder, starch, wheat flour or the like is used. Diarsenic trioxide is used by diluting 50 to 200 times, preferably 70 to 170 times with the edible powder.
If the dilution ratio is less than the lower limit, the influence of toxicity is concerned, and if the dilution ratio exceeds the upper limit, sufficient medicinal effects may not be expected.
気管支喘息などのアレルギー疾患を予防および／または治療するための組成物は、有効成分として三酸化二砒素を含有していればよく、所望により桂枝、黄耆及び甘草の中の少なくとも１種の物質を加えることができる。
桂枝、黄耆及び甘草は、いずれも漢方薬の成分として古来より用いられている。これらを併用することによって、アレルギー疾患の予防・治療上の効果を高めることができる。
桂枝、黄耆及び甘草を配合する場合、各物質の添加量については患者の容態、年齢、その他の要因を考慮して適宜決定すればよいが、通常は各物質いずれも可食性粉末で希釈された三酸化二砒素と同量程度を目安とすればよい。
The composition for preventing and / or treating allergic diseases such as bronchial asthma may contain diarsenic trioxide as an active ingredient, and at least one of katsushi, jaundice and licorice as desired. Substance can be added.
Katsushida, twilight and licorice have all been used since ancient times as ingredients in traditional Chinese medicine. By using these together, it is possible to enhance the preventive and therapeutic effects of allergic diseases.
When blending katsushi, yellow licorice and licorice, the amount of each substance added may be determined appropriately taking into account the patient's condition, age, and other factors, but each substance is usually diluted with edible powder. The amount may be about the same as the amount of diarsenic trioxide formed.
なお、本発明の組成物には、必要に応じて賦形材、増量材、甘味料、香料など医薬分野において通常用いられている補助成分を適宜加えることができる。 In addition, auxiliary components usually used in the pharmaceutical field such as a shaping agent, an extender, a sweetener, and a fragrance can be appropriately added to the composition of the present invention as necessary.
本発明の組成物を患者に投与する場合、アトピー性皮膚炎、喘息、花粉症などのアレルギー疾患の症状や年齢などを考慮して、下記処方の中から適切なものを選択して３週間ほど続けて投与する。通常は、これにより症状の改善がみられるので、投与を中止して経過を観察する。その後、発作が起きた場合は、直ちに対症療法を実施する。すなわち、患者に本発明の組成物を１週間服薬を続けて、その後の経過を観察する。 When the composition of the present invention is administered to a patient, considering the symptoms and age of allergic diseases such as atopic dermatitis, asthma and hay fever, an appropriate one is selected from the following prescriptions for about 3 weeks. Continue to administer. Usually, this improves symptoms, so the administration is discontinued and the course is monitored. Thereafter, if seizures occur, provide symptomatic treatment immediately. That is, the patient continues to take the composition of the present invention for 1 week, and the subsequent course is observed.
以下に、本発明に係るアレルギー疾患の予防・治療用組成物の処方を例示する。
処方１
三酸化二砒素（デンプンによる１００倍希釈物） ２．０ｇ
処方２
三酸化二砒素（デンプンによる１００倍希釈物） ２．０ｇ
桂枝 ２．０ｇ
処方３
三酸化二砒素（デンプンによる１００倍希釈物） ２．０ｇ
桂枝 ２．０ｇ
黄耆 ２．０ｇ
甘草 １．５ｇ
The prescription of the composition for preventing / treating allergic diseases according to the present invention will be exemplified below.
Formula 1
Diarsenic trioxide (100-fold diluted with starch) 2.0g
Formula 2
Diarsenic trioxide (100-fold diluted with starch) 2.0g
Katsura 2.0g
Formula 3
Diarsenic trioxide (100-fold diluted with starch) 2.0g
Katsura 2.0g
Twilight 2.0g
Licorice 1.5g
以下において、本発明を実施例により説明するが、本発明はこれらによって限定されるものではない。 In the following, the present invention will be described with reference to examples, but the present invention is not limited thereto.
実施例１
前記処方３の組成物を、気管支喘息の患者（男性、４２歳）に３週間続けて投与した。
その後、症状が改善されたか否かを判定するため、患者が喘息発作を起こす要因を調べ、患者に該要因と同じ状態を負荷する。本患者は、湿度の高いときに発作を起こすので、室内の湿度を発作が起こりやすい状態に高めた。
経過を１０日間観察したところ、患者は喘息発作を起こさなかったので、症状が改善されたと判定し、退院させた。
Example 1
The composition of Formula 3 was administered continuously for 3 weeks to a patient with bronchial asthma (male, 42 years old).
Thereafter, to determine whether the symptoms have improved, the patient is examined for factors that cause asthma attacks and the patient is loaded with the same condition as the factor. Since this patient has seizures when the humidity is high, the room humidity has been increased to a state where seizures are likely to occur.
After observing the course for 10 days, the patient did not have an asthma attack, so it was determined that the symptoms were improved and the patient was discharged.
実施例２
前記処方２の組成物を、気管支喘息の患者（男性、２５歳）に３週間続けて投与した。この患者は、過労が原因で喘息発作を起こすので、継続的に重作業をさせて発作が起きやすい状態とした。
その結果、軽度の発作が認められたので、対症療法を施し、前記処方を更に１週間服薬を続けた。その後、喘息発作が起こらなかったので、患者を退院させ、以後定期的に経過を観察することとした。
Example 2
The composition of Formula 2 was administered to a patient with bronchial asthma (male, age 25) for 3 weeks. Since this patient had an asthma attack due to overwork, he continued to work hard to make the attack easy to occur.
As a result, mild seizures were observed, so symptomatic treatment was given and the prescription was continued for another week. Thereafter, since no asthma attack occurred, the patient was discharged from the hospital, and the progress was regularly monitored thereafter.
本発明によれば、アトピー性皮膚炎、喘息、花粉症などのアレルギー疾患を、副作用なしに予防および／または治療することができる。
According to the present invention, allergic diseases such as atopic dermatitis, asthma and hay fever can be prevented and / or treated without side effects.
Claims (3)
The composition for prevention / treatment of allergic diseases according to claim 1 or 2, comprising at least one substance selected from katsushi branch, jaundice and licorice, together with diarsenic trioxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005017654A JP2006206461A (en) | 2005-01-26 | 2005-01-26 | Composition for prevention/treatment of allergic disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005017654A JP2006206461A (en) | 2005-01-26 | 2005-01-26 | Composition for prevention/treatment of allergic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2006206461A true JP2006206461A (en) | 2006-08-10 |
Family
ID=36963698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005017654A Pending JP2006206461A (en) | 2005-01-26 | 2005-01-26 | Composition for prevention/treatment of allergic disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006206461A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013147511A (en) * | 2007-02-02 | 2013-08-01 | Panaphix Inc | Use of arsenic compound for treatment of pain and inflammation |
| CN113712993A (en) * | 2021-09-07 | 2021-11-30 | 上海交通大学医学院附属新华医院 | Application of arsenic trioxide and water-soluble substance thereof in preparation of medicine for treating atopic dermatitis |
| DE102007035650B4 (en) | 2006-07-28 | 2021-12-02 | Mitsuba Corp. | Electric motor with reduction gear mechanism |
-
2005
- 2005-01-26 JP JP2005017654A patent/JP2006206461A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007035650B4 (en) | 2006-07-28 | 2021-12-02 | Mitsuba Corp. | Electric motor with reduction gear mechanism |
| JP2013147511A (en) * | 2007-02-02 | 2013-08-01 | Panaphix Inc | Use of arsenic compound for treatment of pain and inflammation |
| US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US10058570B2 (en) | 2007-02-02 | 2018-08-28 | Panaphix Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| CN113712993A (en) * | 2021-09-07 | 2021-11-30 | 上海交通大学医学院附属新华医院 | Application of arsenic trioxide and water-soluble substance thereof in preparation of medicine for treating atopic dermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080038370A1 (en) | Composition and method for treating the effects of diseases and maladies of the upper digestive tract | |
| JP6966998B2 (en) | Formulations for the treatment of oral, throat and airway disorders | |
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| Djerroua et al. | Evaluation of Pistacia lentiscus fatty oil effects on glycemic index, liver functions and kidney functions of New Zealand rabbits | |
| GB2368012A (en) | Preparation for the relief of inflammatory disease | |
| JP2006206461A (en) | Composition for prevention/treatment of allergic disease | |
| KR102091128B1 (en) | Compositions for treatment of cancer-related fatigue | |
| JP2014527971A (en) | pH buffered bioactive glass and method and use thereof | |
| Ibegbu et al. | Anti-inflammatory effects of the aqueous Extracts of plantain roots (Musa Species) | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| JP6590233B1 (en) | Skin disease therapeutic agent and method for producing the same | |
| JP2009505992A (en) | Drunkenness reducing composition comprising hyaluronic acid and activated carbon | |
| JPWO2005032569A1 (en) | Pharmaceutical composition | |
| Das et al. | Molecular modelling technique on interactivity between human carbonic anhydrase 1 and mangiferin for antiulcer activity | |
| JP2009196972A (en) | Medicinal composition | |
| CN108261523A (en) | A kind of Chinese medicine composition and method for treating allergic rhinitis | |
| CN107617018A (en) | A kind of pharmaceutical composition and its application process for being used to treat the herpetic dermatitis of domestic animal | |
| CN101637527A (en) | Application method of amur cork for preparing digestive ulcer medicament | |
| JP2017036228A (en) | Oral composition | |
| Saleman et al. | Antihelicobacter pylori activity by powdered of Ginger, Pomegranates, Arabic gum and Curcuma mixed with honey | |
| Achudume et al. | Effects of the extracts of Pycanthusangolensis against chemically induced acute hepatotoxicity | |
| CN108012530A (en) | For treating the preparation of mucosa injury | |
| CN106075018B (en) | It is a kind of to treat dermopathic external application Chinese medicine lotion and preparation method thereof | |
| EA047803B1 (en) | COMPOSITION FOR THE TREATMENT OF COVID-19 AND RELATED DISORDERS | |
| Obied | Evaluation of Prophylactic Effect of Aqueous Liquorice Root Extract Against Gastric Ulcer in Rats Induced by Ethanol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20060925 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20061011 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20061023 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061107 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070403 |